Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-D24
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intra-arterial
01
Overview
**MSC-D24** is an investigational allogeneic bone marrow-derived human mesenchymal stem cell therapy loaded ex vivo with the tumor-selective oncolytic adenovirus DNX-2401, also known as tasadenoturev or Delta-24-RGD. The mesenchymal stem cells are intended to home to glioma tissue after selective endovascular intra-arterial administration and act as carriers that improve delivery of the viral payload. Released DNX-2401 preferentially replicates in tumor cells with deficient retinoblastoma-pathway signaling, causing oncolysis and promoting antitumor immune responses. MSC-D24 is being evaluated in an active Phase 1 study for recurrent high-grade glioma, including recurrent glioblastoma. ([mdanderson.org](https://www.mdanderson.org/research/departments-labs-institutes/labs/lang-laboratory/research.html))
- Other names
- BM-hMSCs-DNX2401BM-hMSCs-DNX-2401BM-hMSCs-DNX 2401hMSC-D24hMSC-D-24hMSC-D 24hMSCs-D24hMSCs-D-24hMSCs-D 24
02
Targets
αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)RB1 (Retinoblastoma-associated Protein)
Beyond the preview
Go deeper on MSC-D24.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-D24.